LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

29.99 -4.19

Overview

Share price change

24h

Current

Min

29.49

Max

30.85

Key metrics

By Trading Economics

Income

-16M

-97M

Sales

361K

361K

EPS

-1.04

Profit margin

-26,807.202

Employees

437

EBITDA

-17M

-110M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+147.69% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-262M

2.9B

Previous open

34.18

Previous close

29.99

News Sentiment

By Acuity

50%

50%

187 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

21 May 2025, 23:25 UTC

Hot Stocks

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 May 2025, 21:57 UTC

Acquisitions, Mergers, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 May 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefónica's Operations in Uruguay

21 May 2025, 21:01 UTC

Major Market Movers

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 May 2025, 23:49 UTC

Market Talk

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 May 2025, 23:37 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 May 2025, 23:33 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 May 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 May 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 May 2025, 23:32 UTC

Market Talk
Acquisitions, Mergers, Takeovers

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 May 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 May 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 May 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 May 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 May 2025, 23:28 UTC

Earnings

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 May 2025, 23:27 UTC

Earnings

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 May 2025, 23:26 UTC

Earnings

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 May 2025, 23:26 UTC

Earnings

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 May 2025, 23:26 UTC

Earnings

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 May 2025, 23:23 UTC

Acquisitions, Mergers, Takeovers

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 May 2025, 23:22 UTC

Top News

Walmart to Cut 1,500 Corporate Jobs in Restructuring -- WSJ

21 May 2025, 23:22 UTC

Acquisitions, Mergers, Takeovers

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 May 2025, 23:20 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 May 2025, 23:18 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 May 2025, 23:04 UTC

Top News

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

21 May 2025, 21:46 UTC

Top News

NBCUniversal Bids for MLB Rights That Were Dropped by ESPN -- WSJ

21 May 2025, 21:42 UTC

Top News
Acquisitions, Mergers, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 May 2025, 21:14 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefónica's Ops in Uruguay

21 May 2025, 21:07 UTC

Top News

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 May 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

147.69% upside

12 Months Forecast

Average 77.7 USD  147.69%

High 100 USD

Low 53 USD

Based on 11 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

11

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

30.39 / 33.46Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

187 / 382 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.